Ab­b­Vie, Janssen, No­var­tis, Pfiz­er and UCB to joint­ly ad­vance 'dig­i­tal' end­point for atopic der­mati­tis

4 years ago
Pharma

FDA push­es back de­ci­sion on J&J, Leg­end's BC­MA CAR-T

4 years ago
Cell/Gene Tx
FDA+

Per­cep­tive steers Lian­Bio's glob­al­ly con­nect­ed Chi­na strat­e­gy to $325M IPO

4 years ago
Financing
China

Centes­sa pro­vides peek at rare dis­ease drug from ex­treme­ly tiny study, leav­ing sev­er­al ques­tions unan­swered

4 years ago
R&D

Tal Zak­s' post-Mod­er­na fu­ture is now in view as he joins biotech VC blue-chip­per Or­biMed

4 years ago
People

Pfiz­er ap­peals on an­ti-kick­back case; Chi­nese rare dis­ease biotech en­lists UW to re­search Duchenne gene ther­a­pies

4 years ago
News Briefing

HHS seeks to pull Trump-era 'tick­ing time­bom­b' rule that would've put 95% of FDA reg­u­la­tions on the chop­ping block

4 years ago
FDA+

Weeks in­to CEO shake­up, Mi­rati bids adieu to a pair of C-suit­ers with KRAS drug fil­ing around the cor­ner

4 years ago
People

Mi­graine mar­ket­ing wars? Ab­b­Vie, Bio­haven, Eli Lil­ly, Am­gen lead push for at­ten­tion in new­ly com­pet­i­tive space

4 years ago
Pharma
Marketing

An­ti­sense tech­nol­o­gy changed one dev­as­tat­ing dis­ease. Why has­n't it trans­formed oth­ers?

4 years ago
R&D
In Focus

With the help of the NY gov­er­nor's of­fice, Strides Phar­ma ac­quires new man­u­fac­tur­ing site

4 years ago
Manufacturing

Mer­ck dives even fur­ther in­to cy­tokine re­search as deal spree con­tin­ues

4 years ago
Deals

Eli Lil­ly serves up a win over Biden's HHS in drug dis­count court case

4 years ago
Pharma

In key win, Ab­b­Vie lands FDA ap­proval for Al­ler­gan's blurred-vi­sion eye drop

4 years ago
FDA+

FDA safe­ty re­view to hold up Mod­er­na’s Covid-19 vac­cine for teens un­til 2022

4 years ago
FDA+
Coronavirus

As­traZeneca sells two COPD drugs to a fa­mil­iar part­ner as Pas­cal So­ri­ot's on­col­o­gy push march­es on

4 years ago
Deals

Mer­ck de­lays $11.5B Ac­celeron buy­out to give an­titrust watch­dog 'ad­di­tion­al time for re­view'

4 years ago
Deals

Lat­est news on Covid vac­cine OK; No­var­tis' 1 win and 1 flop; Eli Lil­ly and the Alzheimer's puz­zle; End of an era for ...

4 years ago
Weekly

Two decades af­ter Gleevec ap­proval, No­var­tis scores new CML OK for 'wild card' STAMP in­hibitor

4 years ago
R&D

FDA clears Pfiz­er's Covid-19 vac­cine for chil­dren ages 5-11

4 years ago
FDA+
Coronavirus

Covid-19 roundup: Take­da preps roll­out of No­vavax shot for next year — re­port; G20 tar­gets 70% world vac­ci­na­tion ...

4 years ago
Coronavirus

Re­al-world ev­i­dence on Gilead­'s HIV com­bo Bik­tarvy con­firms high ef­fi­ca­cy; Dig­i­tal ther­a­peu­tics firm to trade on ...

4 years ago
News Briefing

An Al­ler­gan psy­chi­atric drug failed late-stage de­pres­sion stud­ies — but Ab­b­Vie is go­ing for ap­proval any­way

4 years ago
R&D
FDA+

Dai­ichi Sankyo scraps ear­ly-stage ADC pro­gram in gas­troin­testi­nal tu­mors af­ter first phase fail

4 years ago
R&D
First page Previous page 620621622623624625626 Next page Last page
A service from the Financial Times